Seeking Novel Therapeutics for Pulmonary Autoimmune and Fibrotic Diseases

A multinational pharmaceutical company is seeking novel treatments for autoimmune and fibrotic diseases of the lung. Our client is particularly interested in novel first-in-class or best-in-class therapeutics for their diseases of interest. 

Approaches of Interest:

• Diseases of interest include asthma, COPD and idiopathic pulmonary fibrosis
• Open to a range of modalities, including small molecules, biologics, oral peptides, RNA-based therapeutics, antibody-oligonucleotide conjugates and in vivo cell therapies
• All novel pathways for the above indications will be considered
• Novel targets with in vivo efficacy data for the above diseases are also of interest

Out of Scope:

• Natural products, gene therapy and ex vivo cell therapy approaches
• Drugs with mature targets (with products in Phase 3 or later stages) unless they have a different modality or mechanism of action 
• Repurposed or reformulated drugs
• Medical devices

Developmental Stages of Interest:

• Opportunities from preclinical to Phase 2 are within scope
• Opportunities with in vivo validation are of highest interest

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Inclusion of any in vivo or clinical data is also encouraged. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and research collaborations.